CMND icon

Clearmind Medicine

1.01 USD
-0.02
1.94%
At close Apr 30, 4:00 PM EDT
After hours
1.00
-0.01
0.99%
1 day
-1.94%
5 days
6.32%
1 month
-2.88%
3 months
-25.19%
6 months
-30.82%
Year to date
-30.34%
1 year
-15.13%
5 years
-99.43%
10 years
-99.43%
 

About: Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Employees: 1

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

13% more funds holding

Funds holding: 8 [Q3] → 9 (+1) [Q4]

0% less capital invested

Capital invested by funds: $5.49M [Q3] → $5.49M (-$3.11K) [Q4]

3.31% less ownership

Funds ownership: 17.3% [Q3] → 13.99% (-3.31%) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for CMND.

Financial journalist opinion

Based on 9 articles about CMND published over the past 30 days

Neutral
GlobeNewsWire
5 days ago
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
TEL AVIV, Israel, April 25, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) has led to the filing of a new international patent application for a proprietary treatment targeting anorexia, bulimia and other eating disorders.
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
Neutral
GlobeNewsWire
5 days ago
Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
Vancouver, Canada, April 25, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the filing of a new international patent application for a proprietary treatment targeting anorexia, bulimia and other eating disorders.
Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
Neutral
GlobeNewsWire
1 week ago
Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites
The Company is now preparing for the enrollment of the first patient to receive Clearmind's innovative treatment as part of the trial
Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites
Neutral
GlobeNewsWire
1 week ago
Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts
Vancouver, Canada, April 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce its upcoming live webinar titled "Gazing Through the Crystal Ball." The event is scheduled for May 21, 2025, at 12:00 PM ET (9:00 AM PT) and will feature a distinguished panel of experts discussing the evolving landscape of psychedelic science and business in the context of changing FDA policies and political climates.
Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts
Neutral
GlobeNewsWire
1 week ago
Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior
Vancouver, Canada, April 17, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that the United States Patent Office has issued a Notice of Allowance for a patent relating to its MEAI treatment for binge behavior.
Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior
Neutral
GlobeNewsWire
2 weeks ago
Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism
Vancouver, Canada, April 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, recently announced it has initiated its Phase I/IIa clinical trial at its first U.S. clinical site, the Johns Hopkins University School of Medicine. The first in human clinical trial will investigate the safety, tolerability and full pharmacokinetic profile of Clearmind's innovative treatment, CMND-100, in Alcohol Use Disorder (AUD) patients. This study is the first clinical application of the Company's proprietary CMND-100 platform and marks a significant milestone in the Company's mission to provide innovative solutions for addictions, weight loss and mental health disorders such as depression and anxiety.
Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism
Neutral
GlobeNewsWire
2 weeks ago
Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder
Vancouver, Canada, April 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that it has initiated its Phase I/IIa clinical trial at its first U.S. clinical site, the Johns Hopkins University School of Medicine. The first in human clinical trial will investigate the safety, tolerability and full pharmacokinetic profile of Clearmind's innovative treatment, CMND-100, in Alcohol Use Disorder (AUD) patients. This study is the first clinical application of the Company's proprietary CMND-100 platform and marks a significant milestone in the Company's mission to provide innovative solutions for addictions, weight loss and mental health disorders such as depression and anxiety.
Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder
Neutral
GlobeNewsWire
3 weeks ago
Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
Vancouver, Canada, April 08, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today the publication of an international patent application in collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”). The patent application covers innovative psychedelic-based compounds designed for the treatment of mental health disorders and addiction.
Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
Neutral
GlobeNewsWire
4 weeks ago
Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment
The clinical trial is designed to evaluate the safety, tolerability and efficacy of Clearmind's innovative, psychedelic-derived, MEAI-based compound in individuals with alcohol addiction
Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment
Neutral
GlobeNewsWire
1 month ago
Clearmind Medicine's FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
Vancouver, Canada, March 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that its innovative drug candidate, CMND-100, has arrived in the United States following successful manufacturing. This marks a key milestone as the Company prepares to initiate its FDA-approved Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder (AUD), a condition affecting over 28 million adults in the U.S. alone.
Clearmind Medicine's FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
Charts implemented using Lightweight Charts™